Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort

Autor: Jolly, M, Devilliers, H, Rúa-Figueroa, I, Azizoddin, Dr, Menor Almagro, R, López Longo, Fj, Ovalles-Bonilla, Jg, Olivé-Marques, A, Rubio-Muñoz, P, Galindo-Izquierdo, M, Fernandez-Nebro, A, Calvo-Alen, J, García de Vicuña-Pinedo, T, Tomero-Muriel, Eg, Uriarte Isacelaya, E, Pecondon-Español, A, Freire-González, M, Blanco, R, Gantes Mora, M, Ibanez Barcelo, M, Montilla-Morales, Ca, José C Rosas-Gómez de Salazar, J, García-Villanueva, J, Vela-Casasempere, P, E Ruiz-Lucea, M, J Toyos-Sáenz-De-Miera, F, Hernández Beiraín, J, Diez Alvarez, E, Bonilla-Hernán, G, Narváez-García, J, Andréu-Sánchez, J, Moreno-Martínez-Losa, M, Sánchez Atrio, A, Horcada, Ml, Cobo-Ibáñez, T, Marras Fernandez-Cid, C, Vazquez Rodriguez, Tr, Salgado-Pérez, E, Torrente, V, Alegre-Sancho, J, Mouriño-Rodriguez, C, Block, Ja, Pego-Reigosa, J.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::216a3cff3fab6ff39b16d51c53851e74
https://u-bourgogne.hal.science/hal-01998107

Multidisciplinary Management of the Adverse Effects of Apremilast

Autor: Daudén Tello, E., Alonso Suárez, J., Beltrán Catalán, E., Blasco Maldonado, C., Herrero Manso, M.C., Jiménez Morales, A., Marín-Jiménez, I., Martín-Arranz, M.D., García-Merino, A., Porta Etessam, J., Rodríguez-Sagrado, M.A., Rosas Gómez de Salazar, J., Trujillo Martín, E., Salgado-Boquete, L.

Publikováno v: Actas Dermo-Sifiliográficas; February 2021, Vol. 112 Issue: 2 p134-141, 8p

Manejo de las manifestaciones extraglandulares del síndrome de Sjögren primario

Autor: Senabre Gallego Jm, Rosas Gómez de Salazar J, Santos Ramírez C

Publikováno v: Reumatología Clínica. 6:6-11

Primary Sjogren's syndrome (pSS) is a chronic systemic autoimmune disease, of slow progression, characterized by lymphocytic infiltration of the exocrine glands, that leads to sicca symptoms, mainly xerophtalmia and xerostomia. It may involve any org

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1ad6e360453d5f390127a4387ca75d5
https://doi.org/10.1016/j.reuma.2010.06.001

Practical application of acid dissociation in monitoring patients treated with adalimumab

Autor: Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, Santos-Soler G, Santos C, Salas-Heredia E, Barber-Vallés X, Molina-García J, AIRE-MB Group

Publikováno v: RHEUMATOLOGY INTERNATIONAL
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Patients treated with adalimumab (ADL) can induce anti-ADL antibodies (AAA) formation that is associated with low drug levels and clinical non-response. But, in the majority of the assays, the measurement of AAA is hampered by the presence of the dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::aa7339afec405c341628bc901b7233e2
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7035